Mylk Antibody

What is MYLK and why are MYLK antibodies essential in research?

MYLK (Myosin Light Chain Kinase) is a calcium/calmodulin-dependent enzyme that phosphorylates myosin regulatory light chains to facilitate myosin interaction with actin filaments, producing contractile activity. This protein plays a crucial role in regulating muscle contraction and relaxation, particularly in smooth muscle cells. Dysregulation of MYLK activity has been linked to various muscle disorders, making it a significant target for therapeutic interventions .

MYLK antibodies are essential research tools because they enable the detection, quantification, and localization of MYLK in various tissue samples and experimental models. These antibodies help researchers investigate the function and regulation of MYLK in physiological and pathological contexts, providing insights into muscle biology, cardiovascular health, and smooth muscle-related diseases .

What are the primary applications of MYLK antibodies in laboratory research?

MYLK antibodies are versatile research tools with multiple validated applications:

These applications allow researchers to study MYLK expression, localization, and function across different experimental contexts . The versatility of these applications enables comprehensive investigation of MYLK's role in various cellular processes.

How should researchers select the appropriate MYLK antibody for specific experimental needs?

Selection of the appropriate MYLK antibody depends on several factors:

• Target species reactivity: Verify that the antibody reacts with your species of interest (human, mouse, rat, etc.) .

• Application compatibility: Ensure the antibody is validated for your specific application (WB, IHC, IF, etc.) .

• Epitope specificity: Consider which region of MYLK you need to target. Some antibodies recognize specific regions, such as amino acids 1765-1914 or 1750-1795 of human MYLK .

• Clonality: Polyclonal antibodies offer broader epitope recognition, while monoclonal antibodies provide higher specificity for a single epitope .

• Validation data: Review published validation images demonstrating the antibody's performance in applications similar to yours .

When testing unknown samples, it's advisable to run positive controls with known MYLK expression patterns to validate your experimental conditions .

What are the optimal sample preparation protocols for MYLK antibody applications?

Optimal sample preparation varies by application:

For Western Blot:

• Use fresh tissue or cells when possible

• Employ RIPA or NP-40 lysis buffers with protease inhibitors

• Heat samples at 95°C for 5 minutes in reducing sample buffer

• Expected molecular weights: ~135 kDa and 210 kDa bands

For Immunohistochemistry:

• Heat-mediated antigen retrieval in citrate buffer (pH 6.0) for 20 minutes

• Block with 10% goat serum to reduce background

• Incubate with primary antibody overnight at 4°C at dilutions of 1:100-1:500

• Use appropriate detection systems (e.g., Strepavidin-Biotin-Complex with DAB chromogen)

For Immunofluorescence:

• Fix cells in 4% paraformaldehyde for 15 minutes

• Permeabilize with 0.1-0.5% Triton X-100

• Block with 1-5% BSA or normal serum

• Incubate with primary antibody at 1:200-1:800 dilution

How can researchers troubleshoot non-specific binding when using MYLK antibodies?

To resolve non-specific binding issues:

• Optimize antibody concentration: Titrate the antibody to find the optimal dilution that provides specific signal with minimal background .

• Improve blocking: Increase blocking time or try alternative blocking agents (BSA, normal serum, commercial blockers).

• Adjust incubation conditions: Reduce incubation temperature or time.

• Include additional washes: Increase the number and duration of wash steps.

• Use validated positive and negative controls: Include tissues known to express or lack MYLK expression .

• Consider pre-absorption: Pre-incubate the antibody with the immunizing peptide to verify specificity .

If high background persists in IHC applications, try alternative antigen retrieval methods or consider using a different detection system .

What controls should be incorporated when using MYLK antibodies in research?

Proper experimental controls are essential:

• Positive tissue controls: Mouse uterus, mouse large intestine, mouse small intestine, and human placenta tissues show high MYLK expression .

• Negative tissue controls: Include tissues with low or no MYLK expression.

• Primary antibody omission: Include a sample treated with all reagents except the primary antibody.

• Isotype control: Use a non-specific antibody of the same isotype and concentration.

• Blocking peptide control: Pre-incubate the antibody with the immunizing peptide to demonstrate specificity .

• Genetically modified samples: When available, use MYLK knockout or knockdown samples as negative controls .

These controls help validate staining patterns and distinguish specific signal from background or artifact .

How can researchers differentiate between MYLK isoforms using antibodies?

MYLK has several isoforms, including the 210 kDa smooth muscle isoform (smMLCK) and the shorter 130-135 kDa non-muscle isoform. To differentiate between isoforms:

• Select epitope-specific antibodies: Choose antibodies raised against regions unique to specific isoforms .

• Use Western blotting with molecular weight markers: The different isoforms appear at distinct molecular weights (~210 kDa for smMLCK and ~135 kDa for non-muscle MLCK) .

• Employ isoform-specific primers: Combine antibody-based approaches with RT-PCR to confirm isoform expression at the mRNA level.

• Consider tissue distribution: Different tissues express distinct isoform patterns; smooth muscle tissues predominantly express the 210 kDa isoform .

When reporting results, clearly specify which MYLK isoform was detected based on molecular weight, tissue source, and antibody specificity .

What are the best practices for quantitative analysis of MYLK using antibody-based methods?

For reliable quantitative analysis:

• Western blot quantification:

  • Include a loading control (β-actin, GAPDH)

  • Use a standard curve with recombinant MYLK protein

  • Employ digital imaging and densitometry software

  • Normalize MYLK signal to loading control

• Immunohistochemistry quantification:

  • Use consistent staining protocols across all samples

  • Employ digital image analysis software for intensity measurement

  • Include calibration standards in each experiment

  • Analyze multiple fields per sample (≥5)

• ELISA-based quantification:

  • Generate a standard curve using recombinant MYLK

  • Run samples in triplicate

  • Include inter-assay controls to normalize between plates

When publishing quantitative results, report detailed methodology including antibody dilutions, exposure times, and image analysis parameters .

How do phosphorylation states affect MYLK antibody binding and what methods can detect activated MYLK?

MYLK function is regulated by phosphorylation, which can affect antibody binding:

• Phosphorylation-specific antibodies: Some specialized antibodies specifically recognize phosphorylated forms of MYLK, particularly at regulatory sites.

• Detection methods for active MYLK:

  • Western blotting: Use phospho-specific antibodies in parallel with total MYLK antibodies

  • Kinase activity assays: Measure MYLK activity using recombinant myosin light chain substrate

  • Proximity ligation assays: Detect interactions between MYLK and calmodulin, indicating activation

• Sample preparation considerations:

  • Include phosphatase inhibitors in lysis buffers

  • Process samples quickly to preserve phosphorylation states

  • Consider using phospho-enrichment techniques prior to antibody-based detection

The phosphorylation status of MYLK is critical for interpreting its functional state in physiological and pathological contexts .

What are the considerations for using MYLK antibodies in multiplex immunofluorescence studies?

For successful multiplex studies:

• Antibody compatibility:

  • Select MYLK antibodies from different host species than other target antibodies

  • Verify that secondary antibodies don't cross-react

  • Consider directly conjugated primary antibodies when available

• Optimization strategies:

  • Perform sequential staining if antibodies require different antigen retrieval methods

  • Titrate each antibody individually before combining

  • Include single-stained controls for spectral overlap assessment

• Signal detection and separation:

  • Use fluorophores with minimal spectral overlap

  • Employ appropriate filter sets or spectral imaging

  • Include an unstained control to account for autofluorescence

• Analysis approaches:

  • Use image analysis software with colocalization capabilities

  • Quantify relative expression levels of MYLK versus other markers

  • Apply appropriate statistical tests for colocalization analysis

Multiplex approaches are particularly valuable for studying MYLK interactions with contractile apparatus components or signaling molecules .

How can MYLK antibodies be utilized to study pathological conditions in different tissue types?

MYLK antibodies can reveal disruptions in normal MYLK expression or localization across various pathologies:

• Cardiovascular disorders:

  • Detect altered MYLK expression in vascular smooth muscle cells in hypertension models

  • Analyze MYLK levels in atherosclerotic plaques

  • Study MYLK distribution in cardiac tissue after ischemic events

• Respiratory conditions:

  • Investigate MYLK expression in airway smooth muscle in asthma models

  • Examine MYLK levels in pulmonary vascular remodeling

• Gastrointestinal disorders:

  • Analyze MYLK distribution in intestinal smooth muscle in motility disorders

  • Study MYLK expression in inflammatory bowel conditions

• Cancer research:

  • Evaluate MYLK expression in cancer tissues, including rectal cancer

  • Correlate MYLK levels with tumor invasiveness and metastatic potential

The validation images in source demonstrate successful MYLK detection in lung, small intestine, placenta, and rectal cancer tissues, providing valuable references for tissue-specific applications.

What are the technical considerations for cross-species applications of MYLK antibodies?

When using MYLK antibodies across different species:

• Sequence homology assessment:

  • Review the degree of conservation in the epitope region across species

  • Higher sequence homology generally predicts better cross-reactivity

• Validation requirements:

  • Verify specificity in each new species with positive and negative controls

  • Compare antibody performance with published expression patterns for that species

• Optimization strategies:

  • Adjust antibody concentration for each species

  • Modify incubation times and temperatures as needed

  • Consider species-specific detection systems

• Application considerations:

  • Cross-reactivity may vary between applications (e.g., WB vs. IHC)

  • Tissue fixation and processing can affect epitope accessibility differently across species

Many MYLK antibodies show reactivity with human, mouse, and rat samples, with some potentially working in other species like horse, as noted in the customer Q&A in source .

How should researchers approach MYLK antibody selection for co-immunoprecipitation experiments?

For successful co-immunoprecipitation (Co-IP) of MYLK and its interaction partners:

• Antibody characteristics:

  • Select antibodies with high affinity and specificity

  • Choose antibodies recognizing epitopes outside interaction domains

  • Consider using multiple antibodies targeting different regions of MYLK

• Buffer optimization:

  • Use mild lysis conditions to preserve protein-protein interactions

  • Include appropriate protease and phosphatase inhibitors

  • Consider adding calcium and calmodulin for stabilizing certain interactions

• Control experiments:

  • Include isotype control antibodies to assess non-specific binding

  • Perform reverse Co-IP when possible

  • Use lysates from cells with MYLK knockdown as negative controls

• Detection strategies:

  • Probe for known MYLK interaction partners (calmodulin, myosin light chain)

  • Consider mass spectrometry to identify novel interacting proteins

  • Verify interactions with orthogonal methods (proximity ligation assay, FRET)

Source notes that MYLK antibodies have been successfully used in Co-IP applications, suggesting their utility in protein interaction studies.

What are the latest methodological advances in MYLK antibody applications for mechanobiology research?

Recent advances in MYLK antibody applications include:

• Live-cell imaging techniques:

  • Cell-permeable fluorescently tagged MYLK antibody fragments

  • Correlation of MYLK localization with force measurements

  • Real-time visualization of MYLK recruitment during mechanotransduction

• Super-resolution microscopy applications:

  • Nanoscale localization of MYLK relative to contractile apparatus

  • Multiplexed imaging of MYLK with other cytoskeletal components

  • Quantitative spatial analysis of MYLK distribution at the nanoscale

• Tissue mechanics correlations:

  • Integration of atomic force microscopy with MYLK immunostaining

  • Correlation of tissue stiffness measurements with MYLK expression patterns

  • Analysis of MYLK distribution in tissues under mechanical strain

• Single-cell analysis approaches:

  • Flow cytometry combined with phospho-specific MYLK antibodies

  • Mass cytometry for multiplexed analysis of MYLK signaling pathways

  • Single-cell western blotting for heterogeneity analysis

These methodological advances enable researchers to link MYLK's molecular functions to cellular and tissue mechanics more directly .

How can researchers resolve common technical issues with MYLK antibodies in Western blot applications?

When troubleshooting Western blot issues:

• No signal or weak signal:

  • Increase antibody concentration (try 1:500 instead of 1:2000)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Load more protein (50-100 μg total protein)

  • Use enhanced chemiluminescence detection reagents

• Multiple unexpected bands:

  • Increase blocking time and wash steps

  • Try different blocking agents (5% milk vs. 5% BSA)

  • Use fresher samples to minimize degradation products

  • Remember MYLK has multiple isoforms (~210 kDa and ~135 kDa)

• High background:

  • Dilute antibody further

  • Increase wash duration and number of washes

  • Use freshly prepared buffers

  • Ensure membrane is completely covered during all steps

• Inconsistent results between experiments:

  • Standardize sample preparation methods

  • Use internal loading controls

  • Prepare fresh transfer buffers

  • Maintain consistent incubation temperatures and times

The recommended dilution ranges for Western blot applications are 1:500-1:2400 or 1:2000-1:10,000 , suggesting that optimization is necessary for each specific experimental system.

What are the critical factors affecting MYLK antibody performance in immunohistochemistry?

For optimal IHC results:

• Fixation considerations:

  • Fixation type (10% neutral buffered formalin recommended)

  • Fixation duration (12-24 hours optimal)

  • Post-fixation tissue processing

• Antigen retrieval methods:

  • Heat-mediated antigen retrieval in citrate buffer (pH 6.0) is recommended

  • Alternative: Tris-EDTA buffer (pH 9.0) for certain tissues

  • Retrieval duration (20 minutes optimal)

• Antibody optimization:

  • Titrate antibody concentration (1:100-1:800 recommended)

  • Optimize incubation time (overnight at 4°C preferred)

  • Select appropriate detection system (Strepavidin-Biotin-Complex with DAB)

• Tissue-specific considerations:

  • Different tissues may require adjusted protocols

  • Some tissues show better results with specific antigen retrieval methods

  • Background staining can vary by tissue type

Source provides validated IHC protocols for multiple tissue types including mouse lung, small intestine, rat small intestine, human placenta, and human rectal cancer tissue, offering valuable reference protocols.

How do storage conditions and handling affect MYLK antibody performance and shelf life?

Proper storage and handling are critical:

• Long-term storage recommendations:

  • Store at -20°C for one year from receipt

  • Avoid repeated freeze-thaw cycles (aliquot upon receipt)

  • Some antibodies contain 50% glycerol to prevent freezing damage

• Working storage considerations:

  • For frequent use, store at 4°C for up to one month

  • Return to -20°C for longer periods between use

  • Monitor for signs of contamination

• Handling precautions:

  • Avoid contamination (use sterile pipette tips)

  • Minimize exposure to light for fluorophore-conjugated antibodies

  • Maintain cold chain during transport between storage and use

• Reconstitution guidelines (for lyophilized products):

  • Add recommended volume of sterile distilled water

  • Allow complete dissolution before use

  • Use within specified timeframe after reconstitution

Following these storage and handling protocols helps maintain antibody performance and extends shelf life, ensuring consistent experimental results over time .